3650 results for «248»
3650 results
How to treat aortic regurgitation
22 May 2026 – From EuroPCR 2026
Explore cutting-edge transcatheter approaches for aortic regurgitation, including first-in-human ATLAS technique, management in LVAD patients, and off-label Myval use. This session reviews clinical challenges and innovative solutions in aortic valve interventions, offering valuable insights from complex procedural experiences.
Left main complications - Part 3
21 May 2026 – From EuroPCR 2026
This session reviews complex complications encountered in left main coronary interventions. It covers causes and management of acute left main occlusion, critical stenosis of coronary buttons, retrieval techniques for ostial stents, and strategies for managing challenging PCI scenarios that may precipitate or resolve catastrophic events.
Left main PCI, what is known and what is new
21 May 2026 – From EuroPCR 2026
This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...
Left main PCI: predictions of risk and long-term clinical outcome
22 May 2026 – From EuroPCR 2026
This session focuses on risk prediction and long-term outcomes following left main percutaneous coronary intervention (PCI). It covers biomarkers like NT-proBNP, hemodynamic predictors, and the impact of comorbidities such as diabetes and chronic kidney disease on patient prognosis over a ten-year follow-up.
Multivessel disease or left main disease
22 May 2026 – From EuroPCR 2026
This session explores revascularisation strategies for patients with multivessel or left main coronary artery disease. It emphasizes the role of intravascular physiology and imaging in guiding treatment decisions and highlights procedural factors that contribute to improved long-term clinical outcomes, supported by complex case discussions.
TAVI interventions for all? From congenital bicuspid valve towards valve-in-valve challenging cases
21 May 2026 – From EuroPCR 2026
This session delves into the complexities of TAVI interventions across diverse challenging cases, including congenital bicuspid valves and valve-in-valve scenarios. It emphasizes complication prevention, decision-making for the Unicorn technique, and the critical role of pre-procedural imaging, illustrated through detailed case studies from Estonia, the Netherlands, and...
When atrial septal closure gets complex
21 May 2026 – From EuroPCR 2026
This session explores the complexities that arise when atrial septal closure procedures become challenging. It covers hybrid retrieval techniques for occluder devices, management of device-related complications mimicking infection, resolution of uncommon complications, and case studies including cryptogenic stroke management in athletes, highlighting procedural intricacies and solutions.
STEMI management around the world
21 May 2026 – From EuroPCR 2026
This session presents a global perspective on STEMI management, addressing strategies to reduce reperfusion delays through nurse-integrated pathways and comparing intracoronary versus intravenous Tirofiban use during primary PCI. It includes epidemiological insights from Rwanda and Egypt, evaluates thrombo-aspiration practices in Sub-Saharan Africa, and examines outcomes in...
RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
01 Sep 2024
Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.
The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...
Author
Insights from the Corevalve US Pivotal and SURTAVI trials
05 Apr 2022
Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.
Author
Author
